Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556975/
https://www.ncbi.nlm.nih.gov/pubmed/34717692
http://dx.doi.org/10.1186/s13045-021-01188-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556975/
https://www.ncbi.nlm.nih.gov/pubmed/34717692
http://dx.doi.org/10.1186/s13045-021-01188-x

Ejemplares similares